Navigating The New Landscape Of Oncology Clinical Trials: A Strategic Imperative For Operations Teams

By Juliane Mills, MS, MPH, Executive Director, Therapeutic Strategy

The oncology clinical trial landscape is growing rapidly and now accounts for about 13% of all registered studies. This boom is driven by a shift toward precision oncology and novel therapies like antibody-drug conjugates. However, this evolution brings unique operational challenges that traditional trial models cannot handle. Working with rare, biomarker-defined patient groups often leads to high screen-fail rates and slow enrollment. Additionally, complex study designs require intense feasibility work, shared screening infrastructure, and prolonged timelines. Sponsors also face a control arm dilemma, as traditional randomized controls are often impractical, forcing a shift toward external control arms that require meticulous data matching.

To navigate this modern landscape, operations and outsourcing teams must move beyond traditional playbooks and adopt a strategic framework. Success requires choosing flexible platform designs, establishing upfront regulatory agreements, and launching centralized pre-screening hubs. Testing infrastructure should incorporate reflexive testing cascades to ensure eligible patients are not missed. Teams must also build real-world data pipelines early to support both trial execution and synthetic control arms. Ultimately, investing in infrastructure purpose-built for the complexity of precision medicine is the only way to accelerate timelines and successfully deliver targeted cancer therapies to patients.